抗体药物的发展现状及展望

Abstract

过了多年的发展，抗体药物已经从原来的多克隆外源抗体过渡到单克隆抗体、人源化抗体、小分子抗体以及目前的全人抗体药物。在临床使用中，抗原靶标及作用机制特点决定了抗抗体药物在临床使用中的安全性和疗效。目前，市场上抗体药物的发展速度要显著高于化学药物，本文就抗体药物发展的历史、现状、市场及未来展望作了简要综述。 After years of development, antibody drugs have made the transition from the polyclonal exogenous antibody to the monoclonal antibodies, humanized antibodies, small molecule antibodies and the fully human antibodies. The safety and effectiveness of therapeutic antibody drugs in clinical practice depend on the nature of the target antigens and the mechanisms. At present, the growth ratio of the antibody drugs is higher than that of chemical compounds in the market. This review provides a brief summary of the history, current state, market and the trend of antibody dugs.